KMG Fiduciary Partners LLC Cuts Stake in AbbVie Inc. $ABBV

Key Points

• KMG Fiduciary Partners cut its AbbVie stake by 18.5% in the second quarter, selling 14,309 shares and retaining 63,078 shares valued at approximately $15.9 million. Institutional investors collectively own 70.23% of ABBV.
• AbbVie reported strong second-quarter results, with revenue up 10.2% year over year to $16.99 billion and EPS of $3.65, beating analyst expectations. The company also declared a quarterly dividend of $1.73 per share, representing a 2.8% yield.
• Growth prospects remain supported by pipeline and product developments: AbbVie plans to acquire Apogee Therapeutics for about $10.9 billion and is seeking a potential new Botox Cosmetic indication. Analysts maintain a “Moderate Buy” consensus with an average price target of $275.70, though valuation, deal execution and biosimilar risks remain concerns.

KMG Fiduciary Partners LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 18.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,078 shares of the company's stock after selling 14,309 shares during the quarter. AbbVie makes up 1.5% of KMG Fiduciary Partners LLC's investment portfolio, making the stock its 19th largest position. KMG Fiduciary Partners LLC's holdings in AbbVie were worth $15,873,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of ABBV. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie in the fourth quarter worth approximately $28,000. Imprint Wealth LLC raised its holdings in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after buying an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID raised its holdings in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after buying an additional 73 shares during the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in AbbVie during the 4th quarter valued at $31,000. Finally, WestEnd Advisors LLC boosted its position in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock valued at $32,000 after buying an additional 85 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Apogee acquisition strengthens immunology pipeline: AbbVie is set to acquire Apogee Therapeutics for approximately $10.9 billion, or $135.11 per share in cash. The deal adds zumilokibart, an investigational therapy for atopic dermatitis, asthma and other inflammatory diseases. Positive Phase 2 data support planned Phase 3 development, potentially helping AbbVie diversify its immunology portfolio and extend growth beyond existing products. The transaction is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
• Positive Sentiment: Botox Cosmetic could gain a fifth indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence, a jaw-muscle condition associated with a wider facial appearance. FDA acceptance does not guarantee approval, but a new aesthetic use could expand Botox’s addressable market and support growth in one of AbbVie’s best-known brands. AbbVie’s Botox Just Got A Step Closer To A Fifth Use
• Positive Sentiment: Analyst sentiment remains constructive: Brokerages maintain a consensus “Moderate Buy” rating, and commentary following second-quarter results characterized ABBV as a potentially undervalued dividend and growth opportunity. AbbVie Receives Consensus Rating of Moderate Buy
• Neutral Sentiment: Strong operating performance is balanced by valuation: AbbVie’s latest quarter exceeded EPS and revenue expectations, with revenue rising 10.2% year over year, driven by SKYRIZI, RINVOQ and neuroscience products. However, the stock’s elevated P/E ratio leaves less room for execution or regulatory disappointments. Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
• Negative Sentiment: Execution and deal risks remain: The Apogee transaction requires approvals and could bring integration costs and development risk if zumilokibart fails to reproduce its Phase 2 results in larger trials. AbbVie must also manage ongoing biosimilar pressure and sustain growth from its core immunology products.

AbbVie Price Performance

ABBV stock opened at $247.86 on Tuesday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The firm has a 50-day moving average of $242.67 and a 200 day moving average of $225.28. The company has a market cap of $437.92 billion, a P/E ratio of 70.02, a PEG ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. During the same period in the previous year, the firm posted $2.97 EPS. The business's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie's payout ratio is currently 195.48%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ABBV shares. Wells Fargo & Company raised their price target on shares of AbbVie from $260.00 to $295.00 and gave the stock an "overweight" rating in a report on Friday, July 10th. Erste Group Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. Canaccord Genuity Group raised their target price on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Morgan Stanley restated an "overweight" rating and set a $296.00 price target on shares of AbbVie in a report on Monday, August 3rd. Finally, Barclays upped their price target on AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $275.70.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source